These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 36604718)

  • 1. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
    Li Y; Yang W; Zheng Y; Dai W; Ji J; Wu L; Cheng Z; Zhang J; Li J; Xu X; Wu J; Yang M; Feng J; Guo C
    J Exp Clin Cancer Res; 2023 Jan; 42(1):6. PubMed ID: 36604718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.
    Shi Z; Li Z; Jin B; Ye W; Wang L; Zhang S; Zheng J; Lin Z; Chen B; Liu F; Zhang B; Ding X; Yang Z; Shan Y; Yu Z; Wang Y; Chen J; Chen Q; Roberts LR; Chen G
    Clin Transl Med; 2023 Jun; 13(6):e1300. PubMed ID: 37337470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma.
    Dong FL; Xu ZZ; Wang YQ; Li T; Wang X; Li J
    J Nanobiotechnology; 2024 May; 22(1):298. PubMed ID: 38811968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCM4 potentiates evasion of hepatocellular carcinoma from sorafenib-induced ferroptosis through Nrf2 signaling pathway.
    Liu X; Zhang F; Fan Y; Qiu C; Wang K
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113107. PubMed ID: 39276458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism.
    Shueng PW; Chan HW; Lin WC; Kuo DY; Chuang HY
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.
    Ji J; Cheng Z; Zhang J; Wu J; Xu X; Guo C; Feng J
    J Cell Mol Med; 2024 Apr; 28(8):e18335. PubMed ID: 38652216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.
    Xu FL; Wu XH; Chen C; Wang K; Huang LY; Xia J; Liu Y; Shan XF; Tang N
    Cell Death Dis; 2023 Jan; 14(1):22. PubMed ID: 36635256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma.
    Huang CY; Chen LJ; Chen G; Chao TI; Wang CY
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.
    Hu Y; Luo Z; Cai S; Xie Q; Zheng S
    Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis.
    Hsu TW; Su YH; Chen HA; Liao PH; Shen SC; Tsai KY; Wang TH; Chen A; Huang CY; Shibu MA; Wang WY; Shen SC
    Aging (Albany NY); 2023 Jul; 15(13):6503-6525. PubMed ID: 37433225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tmem39b promotes tumor progression and sorafenib resistance by inhibiting ferroptosis in hepatocellular carcinoma.
    Zhuang M; Zhang X; Li LU; Wen L; Qin J
    Oncol Res; 2024; 32(8):1347-1357. PubMed ID: 39055886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2.
    Lai Y; Han X; Xie B; Xu Y; Yang Z; Wang D; Li W; Xie Y; Song W; Zhang X; Xia JQ; Zhang P
    Cancer Sci; 2024 Jul; 115(7):2220-2234. PubMed ID: 38623968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
    Li J; Li Y; Wang D; Liao R; Wu Z
    J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.
    Huang W; Chen K; Lu Y; Zhang D; Cheng Y; Li L; Huang W; He G; Liao H; Cai L; Tang Y; Zhao L; Pan M
    Neoplasia; 2021 Dec; 23(12):1227-1239. PubMed ID: 34768109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long Noncoding RNA URB1-Antisense RNA 1 (AS1) Suppresses Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma by Driving Ferritin Phase Separation.
    Gao Y; Tong M; Wong TL; Ng KY; Xie YN; Wang Z; Yu H; Loh JJ; Li M; Ma S
    ACS Nano; 2023 Nov; 17(22):22240-22258. PubMed ID: 37966480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TEA Domain Transcription Factor 1 Inhibits Ferroptosis and Sorafenib Sensitivity of Hepatocellular Carcinoma Cells.
    Li H; Lan H; Zhang M; Zhao F; An N; Yi C
    Dig Dis Sci; 2023 Jul; 68(7):3070-3082. PubMed ID: 36680650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
    Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y
    J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondrial GCN5L1 acts as a novel regulator for iron homeostasis to promote sorafenib sensitivity in hepatocellular carcinoma.
    Hu X; Zhang P; Li S; Zhang J; Wang D; Wang Z; Zhu L; Wang L
    J Transl Med; 2024 Jun; 22(1):593. PubMed ID: 38918793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma.
    Yang M; Wu X; Hu J; Wang Y; Wang Y; Zhang L; Huang W; Wang X; Li N; Liao L; Chen M; Xiao N; Dai Y; Liang H; Huang W; Yuan L; Pan H; Li L; Chen L; Liu L; Liang L; Guan J
    J Hepatol; 2022 May; 76(5):1138-1150. PubMed ID: 35101526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
    Yang C; Lu T; Liu M; Yuan X; Li D; Zhang J; Zhou L; Xu M
    Phytomedicine; 2023 Mar; 111():154668. PubMed ID: 36657316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.